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Gy daily fractions for oropharynx/oral cavity and positive lymph 
nodes. Lower doses were used for patients treated with concomitant 
chemotherapy: 66 Gy in 2.2 Gy daily fractions for tumor and 60 Gy in 
2 Gy daily fractions for oropharynx/oral cavity and positive lymph 
nodes. Negative lymph nodes were irradiated with equal dose for both 
groups: 54 Gy in 1.8 Gy daily fractions. Chemotherapy (either 
carboplatin 100mg/m2 or cisplatin 80 mg/m2) was given intravenously 
every 3 weeks. 
Results: The median follow-up was 24 months (range 3-53). Complete 
response rate for the oropharynx and the oral cavity group was 87% 
and 87.5% , respectively. The 1 and 2-year Overall Survival (OS) and 
Disease Free Survival (DFS) rate for the oropharynx group was 80%, 
73.3%, 73.3% and 73.3% respectively. For the oral cavity group, 1 and 
2-year OS and DFS rates were 62.5%. Concerning acute toxicity, no 
patient developed grade ≥3. G2 mucositis, dysphagia and dermatitis 
rates were 87%, 69.6% and 47.9%, respectively. Concerning late 
toxicity, maximum grade observed was G2 xerostomia in 5.6% of 
cases.  
Conclusions: HT appears to achieve encouraging clinical outcomes in 
terms of response, survival and toxicity rates.  
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Purpose/Objective: Incidence of Oral Cavity Squamous Cell 
Carcinoma (OCSCC) in India is amongst the highest in the world. The 
analysis highlights time lags in presentation and treatment along with 
disease control outcomes.  
Materials and Methods: Unselected case notes of 56 patients with 
OCSCC who underwent surgery at Tata Medical Center (TMC), between 
May 2011 to October 2012 were analysed. Time from presentation to 
consultation at TMC, consultation to first surgery, T, N, M and overall 
stage (AJCC 7) were analysed. Time lag between surgery to adjuvant 
treatment (radiotherapy (RT) or chemoradiotherapy (CTRT) to a dose 
of 60-63Gy in 30 fractions), disease free survival, distant metastases 
free survival, local recurrence and cases lost to follow up rates were 
calculated after a median follow up of 6 months. 
Results: The mean age was 52.9 years with 25 (44.6%) patients having 
oral tongue, 18 (32.14%) buccal mucosa disease. On presentation, 14 
(25%), 13 (23.2%), 23 (41%) and 5 (8.9%) patients had T4, T3, T2 and 
T1 disease respectively. 12 (21.4%), 15 (26.7%) and 5 (8.9%) had N1, 
N2 or N3 disease. 29 (51.7%), 16 (28.5%), 9 (16%) cases presented with 
stage IV, III and II disease. The time lag between first symptom to that 
when patient was seen in TMC was 4.5months (range 0-24 months). 5 
(8.9%) cases received neo adjuvant chemotherapy prior to surgery. 
Time lag between when seen at TMC and when surgery was performed 
was 1 month (range 0-3months) with 91% cases requiring some form of 
reconstructive procedure during surgery. Median time between 
surgery and adjuvant treatment was 1.5 months (range1-2 months). 27 
(48.2%) cases completed concurrent CTRT with a platinum agent, 26 
(46%) received RT only whist 2 patients refused to have RT and one 
received RT outside the country. 7 cases (12.5%) developed local 
recurrence. 4 (7.1%) cases developed distant metastases of which 
3(75%) developed both local and distant disease. 45 (80.3)% patients 
were alive at 6 months, 3 patients were lost to follow up. 4 deaths 
occurred within 1 month post treatment prior to any follow up and has 
been attributed to aspiration related symptoms. 
Conclusions: Indian patients present late, with more advanced 
disease at a younger age, majority with a significant time lag prior to 
presenting to the tertiary center. Although patients complete their 
treatment lack of community support could result in toxicities prior to 
the first follow up (1 month post RT) requiring early intervention by a 
community nurse. Early local or distant metastases in this patient 
group could raise the possibility of an aggressive biological subtype of 
OCSCC.  
   
EP-1024   
Role of gefitinib with chemoradiation in locally advanced head and 
neck cancer  
C. Singh1, R. Sharma1, O.P. Sharma1 
1S.M.S. Medical College and Attached Hospitals, Department of 
Radiotherapy and Clinical Oncology, Jaipur, India  
 
Purpose/Objective: To assess efficacy of geftinib along with 
chemoradiation (cisplatin + radiotherapy) in comparision to 
chemoradiation alone in management of locally advanced head and 
neck cancer. 
Materials and Methods: 60 previously untreated histologically proven 
patients of squamous cell carcinoma of head and neck cancer 
attending department of radiotherapy, SMS hospital, Jaipur from june 
2011 to may 2012 were taken and divided into two groups- control (30 
patients) and study (30 patients). The control group received cisplatin 
30mg/m2 iv weekly along with radiotherapy, starting from day 1 of 
radiotherapy. The study group received gefitinib 250 mg po starting 1 
week prior to commencement or radiotherapy followed by cisplatin 
30mg/m2 iv weekly along with radiotherapy, starting from day 1 of 
radiotherapy till its completion. Dose of radiotherapy was 66Gy/33Fr/ 
6.3 weeks. Patients were followed monthly upto 6 months. 
Results: The acute and late radiation toxicity on skin, mucosa and 
hemogram was variable in control and study groups but more in study 
group. Combined for all T stage tumors complete response (CR) for 
control and study groups was 24 (80%) and 17 (56%) respectively. The 
overall response (tumor+nodal response) for all stages was found 
statistically non-significant. Disease status at 6th month follow up in 
control and study group was: no evidence of disease- 21 (70%) versus 
27(90%), residual disease- 8 (27%) versus 3(10%). At the median follow 
up of 15 months, 16 patients of study group were on follow up,11 of 
which had complete response and 5 had recurrent disease. In control 
group, 10 patients were on follow up of which 7 had complete 
response and 3 had recurrent disease. 
Conclusions: Chemoradiation remains mainstay of treatment for head 
and neck carcinoma patients. EGFR is the most expressed receptor in 
squamous cell carcinoma of head and neck. The present study shows 
that targeted therapy with gefitinib (EGFR tyrosine kinase inhibitor) 
and chemoradiation is well tolerated with some enhanced but 
manageable toxicities and has shown to improve local control and 
survival in locally advanced head and neck cancer.  
   
EP-1025   
Clinical outcomes of daily image guided helical tomotherapy in 
head and neck cancers 
M.N. Duma1, T. Müller1, S. Kampfer1, S. Pigorsch1, M. Molls1 
1Klinikum Rechts der Isar TU München, Department of Radiation 
Oncology, München, Germany  
 
Purpose/Objective: The aim of the study was to analyze the overall 
outcomes, patterns of failure and toxicities of postoperative, daily 
image guided head and neck helical tomotherapy (HT). 
Materials and Methods: 86 patients (67 male and 19 female) were 
treated with HT between June 2007 and August 2010 at our 
institution. Overall, the median age was 58 years. The majority of 
patients had a T2(48%,n=41);N2(55%,n=47) tumor, with a total of 30 
patients with ECE. The median prescribed dose to the PTV was 64 Gy. 
42 patients underwent conconcomitant platinum based chemotherapy.  
Results: Median follow-up time was 32 months. 2-year (3-year) overall 
survival, disease-free survival, and locoregional control were 
81%(73%), 77%(63%), and 82%(74%), respectively. Overall 15 patients 
developed a locoregional failure (12 local, 3 regional): 14 infield , 1 
marginal field. 13 patients developed distant metastasis. At 2 years 2 
patients had grade 3 dysphagia (CTCAE v4.0). No further grade 3/4 
toxicitieswere observed. 
Conclusions: Our results show that daily image guided helical 
tomotherapy is effective and safe in terms of local disease control and 
avoidance of persistent grade 3/4 late toxicities. 
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Purpose/Objective: Radiation induced thyroid abnormality after 
radiotherapy (RT) of nasopharyngeal cancer (NPC) has been reported 
in many studies. Apart from the thyroid gland, the pituitary gland is 
also usually irradiated to high dose for patients with skull base 
involvement. Since the thyroid function is controlled by the pituitary 
gland through the hypothalamic-pituitary-thyroid axis, the hypothesis 
of this study was that the combined effect of high radiation dose to 
the thyroid and pituitary glands would increase the risk of thyroid 
abnormality.  
Materials and Methods: 65 NPC patients with stages II to IV treated by 
RT were recruited. Before RT, baseline thyroid hormone levels of each 
patient including fT3, fT4 and TSH were taken. A 7-beam intensity 
modulated radiotherapy (IMRT) plan was generated for each patient 
following the local planning protocol. The doses to the thyroid and 
pituitary glands were calculated by generating their dose volume 
histograms (DVH). The patients were divided into 4 categories 
according to the doses to the thyroid and pituitary glands, where 'high 
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dose' was defined as a mean gland dose of above 50 Gy. The four 
groups were: high thyroid and pituitary doses (HTHP group); high 
thyroid and low pituitary doses (HTLP group); low thyroid and high 
pituitary doses (LTHP group) and low thyroid and pituitary doses (LTLP 
group). Repeated measurements of the fT3, fT4 and TSH were taken 
at 3, 6, 12 and 18 months after completion of radiotherapy. Any 
abnormal thyroid hormone levels and incidences of hypothyroidism 
were identified and analysed with respect to the four different 
patient groups defined above.  
Results: In general, the thyroid gland received relatively higher dose 
than the pituitary gland, with the average mean and D50 thyroid dose 
about 60% higher than that of the pituitary. 22 patients (33.8%) and 17 
patients (26.2%) received high mean thyroid and pituitary doses of 
over 50 Gy respectively. At the 18 months post-RT, 4 patients (6.2%) 
developed overt hypothyroidism, 9 (13.8%) developed subclinical 
hypothyroidism and 2 (3.1%) developed central hypothyroidism (Table 
1). The incidence of abnormal thyroid function was highest in the 
HTHP group, in which 5 out of 6 cases (83.3%) developed 
hypothyroidism followed by the HTLP group with an incidence of 50%. 
The LTHP and LTLP groups showed much lower incidence of 
hypothyroidism (<10%). 
 
  
Conclusions: Patients who received both high thyroid and pituitary 
glands doses carried the highest risks of abnormal thyroid functions. 
High thyroid dose was a more influential factor than high pituitary 
dose in inducing post-RT hypothyroidism. Therefore, measure to keep 
the mean thyroid dose below 50 Gy in treatment planning was 
essential to minimize the thyroid complications. 
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Purpose/Objective: External radiation therapy (ERT) and 
chemotherapy are currently used for the treatment of head and neck 
cancer. These therapies are often associated with mucositis and 
xerostomia while hyperpigmentation of the tongue is a rare event. 
The aim of our study was to study all cases of dark tongue in patients 
(pts) treated with ERT on the head and neck area by performing a 
routine microbiological test and looking for possible correlations with 
ERT or other therapies administered. 
Materials and Methods: In a period of 9 months we observed 10 cases 
of hyperpigmentation of tongue. Four pts underwent radical surgery 
before ERT, 2 pts had conservative surgery. Six pts were treated 
concurrent with chemotherapy. Eight patients were treated with 
3DCRT, 2 pts with IMRT. The evaluation of acute toxicity was made 
using the RTOG criteria. Lingual swabs were performed at the 
appearance of lingual discoloration. An assessment of the dose-volume 
histogram (DVH) was carried out for each patient. 
  
Results: Pts developed hyperpigmentation of tongue at a mean dose 
of 40,65 Gy (range 22 – 68 Gy). For all pts, the brown coloration was 
on the anterior half of dorsal surface of mobile tongue without pain, 
burning sensation or other type of tongue distress. Mucositides G2 
were observed in 5 pts and G1 in 1 pt. Salivary gland toxicity G2 was 
detected in 5 pts and G1 in 1 pt. No pts developed hematologic 
toxicity. In only one case (5%) an infection by two microorganisms 
(Klebsiella pneumoniae and Candida spp.) was reported, while in all 
other cases there were monomicrobic infections represented in 50% of 
the cases by Candida spp, in the 45% by gram-negative bacterial 
pathogens (Acinetobacter lwoffii, Acinetobacter Baumannii, 
Enterobacter cloacae, Pseudomonas spp.).  From an initial 
assessment, evaluating the DVH data, we did not observe a direct 
correlation between the appearance of hyperpigmentation of tongue 
and the dose absorbed by the tongue nor by parotid glands. We did 
not find a correlation between the initial infection and the 
administration of chemotherapy. All patients assumed topical therapy 
for the prevention and palliative treatment of xerostomia and 
mucositis. In order to treat hyperpigmentation of the dorsal surface of 
tongue, five patients (2 with Candida and 3 with bacterial infection) 
did not assume any therapy while the others were treated with 
systemic antifungal therapy or with antibiotic depending by the 
microbial agent reported. It may be stated that administration of 
systemic targeted therapy did not give any advantage as to the time 
of resolution of the black tongue. 
Conclusions: We believe that for all patients, the hyperpigmentation 
of tongue is related to the changed microenvironmental conditions of 
the oral cavity favoring the development of opportunistic 
microorganisms. We would also like to emphasize the need for a 
microbiological swab test before prescribing any drug to subjects with 
a black tongue discoloration.  
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Purpose/Objective: Radiotherapy alone (RT) or in combination with 
chemotherapy (CRT) is a standard of care for patients in locally 
advanced squamous cell carcinoma head and neck cancer (LA-HNSCC). 
However, RT is associated with side effects, which can have a 
significant impact on the QoL. The purpose of this study was to 
investigate the longitudinal changes in QoL for patients with LA-
HNSCC following RT or CRT. 
Materials and Methods: From September 2008 to February 2010, 205 
patients with LA-HNSCC were included. The data pertaining to their 
QoL were collected using the European Organization for Research and 
Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-
C30) and the EORTC Head and Neck Module(QLQ-H&N35) before RT 
and 12 months after the end of RT. The data of all items and scales of 
the EORTC QLQ-C30 and the EORTC QLQ-H&N35 were transformed to a 
0–100 scale for presentation according to the guidelines of the EORTC. 
For statistical evaluation the student t-test was performed with 
significance level of p< 0.05. 
Results: In general, during the 1 year follow-up after the end of RT 
the QoL of patients increased and the global QoL was not statistically 
different than prior RT. The most significant improvement was 
observed for the following issues: appetite, pain, nausea and 
vomiting, and fatigue. However, after 1 year from the end of RT the 
QoL for many subscales is still lower than prior treatment. For 
